Different antibody response to a neutralizing epitope of human cytomegalovirus glycoprotein B among seropositive individuals
Minoru Ayata
Department of Microbiology, Medical Research Institute, Kanazawa Medical University, Ishikawa, Tokyo, Japan
Search for more papers by this authorTohru Sugano
Teijin Institute for Biomedical Research, Tokyo, Japan
Search for more papers by this authorTsugiya Murayama
Department of Microbiology, Medical Research Institute, Kanazawa Medical University, Ishikawa, Tokyo, Japan
Search for more papers by this authorDaitoku Sakamuro
Department of Microbiology, Medical Research Institute, Kanazawa Medical University, Ishikawa, Tokyo, Japan
Search for more papers by this authorTsutomu Takegami
Division of Tropical Medicine, Medical Research Institute, Kanazawa Medical University, Ishikawa, Tokyo, Japan
Search for more papers by this authorYoh-Ichi Matsumoto
Teijin Institute for Biomedical Research, Tokyo, Japan
Search for more papers by this authorCorresponding Author
Toru Furukawa M.D.
Department of Microbiology, Medical Research Institute, Kanazawa Medical University, Ishikawa, Tokyo, Japan
Department of Microbiology, Kanazawa Medical University, Ishikawa, Japan===Search for more papers by this authorMinoru Ayata
Department of Microbiology, Medical Research Institute, Kanazawa Medical University, Ishikawa, Tokyo, Japan
Search for more papers by this authorTohru Sugano
Teijin Institute for Biomedical Research, Tokyo, Japan
Search for more papers by this authorTsugiya Murayama
Department of Microbiology, Medical Research Institute, Kanazawa Medical University, Ishikawa, Tokyo, Japan
Search for more papers by this authorDaitoku Sakamuro
Department of Microbiology, Medical Research Institute, Kanazawa Medical University, Ishikawa, Tokyo, Japan
Search for more papers by this authorTsutomu Takegami
Division of Tropical Medicine, Medical Research Institute, Kanazawa Medical University, Ishikawa, Tokyo, Japan
Search for more papers by this authorYoh-Ichi Matsumoto
Teijin Institute for Biomedical Research, Tokyo, Japan
Search for more papers by this authorCorresponding Author
Toru Furukawa M.D.
Department of Microbiology, Medical Research Institute, Kanazawa Medical University, Ishikawa, Tokyo, Japan
Department of Microbiology, Kanazawa Medical University, Ishikawa, Japan===Search for more papers by this authorAbstract
The amino-terminal portion of human cytomeg-alovirus glycoprotein B (HCMV-gB) was expressed as a fusion protein to analyze the neutralizing epitope recognized by human monoclonal antibody C23 and the humoral immune response to this epitope. The linear neutralizing epitope was further localized to the pep-tide within 17 amino acids (position 68-84) which were conserved between two HCMV laboratory strains. Ten out of 17 HCMV-seropositive human sera contained the antibody against this epitope. Although seven sera were negative for reacting with the fusion protein, the viruses isolated from the same patients retained the epitope. The immunogenicity of the epitope and the possible application of C23 human monoclonal antibody for passive immunization against HCMV infections are discussed. © 1994 Wiley-Liss, Inc.
References
- Basgoz N, Qadri I, Navarro D, Sears A, Lennette E, Youngblom J, Pereira L (1992): The amino terminus of human cytomegalovirus glycoprotein B contains epitopes that vary among strains. Journal of General Virology 73: 983–988.
- Britt WJ, Vugler L, Butfiloski EJ, Stephens EB (1990): Cell surface expression of human cytomegalovirus (HCMV) gp55—116 (gB): Use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. Journal of Virology 64: 1079–1085.
- Shou S (1992): Comparative analysis of sequence variation in gp116 and gp55 components of glycoprotein B of human cytomegalovirus. Virology 188: 388–390.
- Condie RM, O'Reilley RJ (1984): Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Randomized trial in bone marrow transplant recipients. American Journal of Medicine 76: 134–141.
- Cranage MP, Kouzarides T, Bankier AT, Satchwell S, Weston K, Tom-linson P, Barrell B, Hart H, Bell SE, Minson AC, Smith GL (1986): Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in re-combinant vaccinia virus. EMBO Journal 5: 3057–3063.
- Furukawa T, Hornberger E, Sakuma S, Plotkin SA (1975): Demonstration of immunoglobulin G receptors induced by human cytomegalovirus. Journal of Clinical Microbiology 2: 332–336.
- Furukawa T, Funamoto Y, Ishida S, Kamiya H (1987): The importance of primary cytomegalovirus infection in childhood cancer. European Journal of Pediatrics 146: 34–37.
-
Ho M
(1991):
“ Cytomegalovirus: Biology and Infection,”.
2nd ed.
New York:
Plenum Publishing Corp.
10.1007/978-1-4757-9942-2 Google Scholar
- Kniess N, Mach M, Fay J, Britt WJ (1991): Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus. Journal of Virology 65: 138–146.
- Landini M, Michelson S (1988): Human cytomegalovirus proteins. Progress in Medical Virology 35: 152–185.
- Maniatis TE, Fritsch EF, Sambrook J (1982): “ Molecular Cloning: A Laboratory Manual.” New York: Cold Spring Harbor Laboratory.
- Marshall GS, Rabalais GP, Stout GG, Waldeyer SL (1992): Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. Journal of Infectious Diseases 165: 381–384.
- Masuho Y, Matsumoto Y, Sugano T, Fujinaga S, Minamishima Y (1987): Human monoclonal antibodies neutralizing human cytomegalovirus. Journal of General Virology 68: 1457–1461.
- Masuho Y, Matsumoto Y, Sugano T, Tomiyama T, Sasaki S, Koyama T (1990): Development of a human monoclonal antibody against cytomegalovirus with the aim of a passive immunotherapy. In CAK Borrebaeck, JW Larrick (eds): “ Therapeutic Monoclonal Antibodies.” New York: Stockton Press, pp 187–207.
- Meyer H, Masuho Y, Mach M (1990): The gp116 of the gp58-116 complex of human cytomegalovirus represents the amino-terminal part of the precursor molecule and contains a neutralizing epitope. Journal of General Virology 71: 2443–2450.
- Meyer H, Sundqvist V-A, Pereira L, Mach M (1992): Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. Journal of General Virology 73: 2375–2383.
- Murayama T, Natsuume-Sakai S, Shimokawa K, Furukawa T (1986): Fc receptor(s) induced by human cytomegalovirus bind differentially with human immunoglobulin G subclasses. Journal of General Virology 67: 1475–1478.
- Rasmussen L (1990): Immune response to human cytomegalovirus infection. Current Topics in Microbiology and Immunology 154: 221–254.
- Saiki RK, Gelfand DH, Stoffel S, Scharp SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA (1988): Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239: 487–491.
- Shimokawa K, Murayama T, Ishida S, Furukawa T (1987): Analysis by immunoblotting of human cytomegalovirus antibody in sera of renal transplant recipients. Journal of Medical Virology 21: 339–346.
- Spaete RR, Thayer RM, Probert WS, Masiarz FR, Chamberlain SH, Rasmussen L, Merigan TC, Pachl C (1988): Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage. Virology 167: 207–225.
- Tomiyama T, Masuho Y (1990): Antiviral activities of a human monoclonal antibody against human cytomegalovirus. In C Lopez, (ed): “ Immunology and Prophylaxis of Human Herpesvirus Infections.” New York: Plenum Press, pp 105–113.
- Utz U, Britt WJ, Vugler L, Mach M (1989): Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus. Journal of Virology 63: 1995–2001.
Citing Literature
